Nutra Pharma has announced that its Chairman and CEO, Rik J. Deitsch, was interviewed by the Senior Editor of CEO-CFO, Lynn Fosse. The interview, which will be published in late-October, focuses on Nutra Pharma’s launch of its pain reliever, Cobroxin, and the company’s growth strategies.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its Chairman and CEO, Rik J. Deitsch, has completed an interview with leading online financial publication, CEO-CFO.
In the interview, Mr. Deitsch discusses the launch of Cobroxin, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain developed by Nutra Pharma’s drug discovery subsidiary, ReceptoPharm. Additionally, Mr. Deitsch also discusses the company’s growth strategy as it relates to future potential acquisitions and out-licensing partnerships.
“It is a very exciting time for Nutra Pharma. As the company realizes its first significant revenues through the sale of our drug products, it is more important than ever that we share the story of Nutra Pharma with our investors and the public,” explained Mr. Deitsch. “As excitement builds around the launch of Cobroxin and the development of our other leading drug indications, we plan to extend our communication outreach to include consumer-oriented media outlets in addition to financial industry publications,” he concluded.
CEO-CFO is a weekly online financial publication that combines news and interviews from key executives at publicly-traded companies and venture capital firms in the United States and abroad. The interview with Mr. Deitsch is scheduled for publication in late-October. Once the interview is published on CEO-CFO, a direct link will be made available on the Nutra Pharma website.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The interview given by Rik J. Deitsch for CEO-CFO should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.